Supernus Pharmaceuticals | SUPN - Gross Profit On Sales

Stock Price
54.73
Daily Change
-1.02 -1.83%
Monthly
11.83%
Yearly
70.71%
Q1 Forecast
49.28

Supernus Pharmaceuticals reported $164.04M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.54B 625M Dec/2025
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
Aurora Cannabis CAD 32.29M 4.34M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 199.58M 3.46M Dec/2025
Eisai JPY 168.85B 17.02B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pacira USD 142.25M 11.34M Dec/2025
Perrigo USD 362.2M 14.9M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
United Therapeutics USD 315.5M 286.6M Dec/2025
Xeris Pharmaceuticals USD 63.38M 3.74M Sep/2025